Compound 2

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Agencia Estatal de Investigación and 4 more

Animals1

Outcomes

Cellular senescence

downin cells1

1 study

Compound 2 decreases cellular senescence in cells.
“Treatment with UCM-18142 results in significant improvements in cellular phenotype in both HGPS patient-derived cells and a murine model, including enhanced proliferation, reduced senescence markers”
Cellsin HGPS patient-derived cells and a murine model
First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria
Advanced science (Weinheim, Baden-Wurttemberg, Germany)23 Mar 2026

Latest

1 in 12 months

Advanced Science23 Mar

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

Experiments in miceProgeria

Paper

Compound 2

Outcomes

Latest

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

Related